Literature DB >> 30213435

A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.

Amir Jazaeri1, Robert L Coleman2, Anil K Sood2, Michael M Frumovitz2, Pamela T Soliman2, Aaron Shafer2, Jeffry J Cutrera2, Marlana Klinger2, Sara E Sharafi2, Cynae A L Johnson2, Valerie F Villanueva2, Emily M Hinchcliff2, Andrea Dickens3, Katherine E Cain3, Jaime E Anderson4, Karen H Lu2, Shannon N Westin2.   

Abstract

The success of targeted and immune therapies in other malignancies has led to an exponential increase in the number of active and pending clinical trials using these therapeutic approaches in patients with gynecologic cancers. These novel investigational agents are associated with unique and potentially life-threatening toxicities and many require special multidisciplinary logistical considerations. The objective of this review is to describe a practical approach for the safe implementation of targeted and immune therapies in academic gynecologic oncology practices based on our experience at M.D. Anderson Cancer Center.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Adoptive cell therapy; Checkpoint inhibitor; Clinical trials; Immune-related adverse events; Immunotherapy; Targeted therapy

Mesh：

Substances：

Year:  2018        PMID： 30213435      PMCID： PMC6235625          DOI： 10.1016/j.ygyno.2018.08.037

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN： 0090-8258            Impact factor:   5.482


  12 in total

Review 1.  Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.

Authors:  Paul Mayor; Kristen Starbuck; Emese Zsiros
Journal:  Gynecol Oncol       Date:  2018-05-24       Impact factor: 5.482

2.  Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  J B A G Haanen; F Carbonnel; C Robert; K M Kerr; S Peters; J Larkin; K Jordan
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

Review 3.  Adoptive T-Cell Therapy for Cancer.

Authors:  James C Yang; Steven A Rosenberg
Journal:  Adv Immunol       Date:  2016-02-03       Impact factor: 3.543

4.  Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.

Authors:  Sanja Stevanović; Lindsey M Draper; Michelle M Langhan; Tracy E Campbell; Mei Li Kwong; John R Wunderlich; Mark E Dudley; James C Yang; Richard M Sherry; Udai S Kammula; Nicholas P Restifo; Steven A Rosenberg; Christian S Hinrichs
Journal:  J Clin Oncol       Date:  2015-03-30       Impact factor: 44.544

Review 5.  Immunotherapy in Gynecologic Cancers: Are We There Yet?

Authors:  Janelle B Pakish; Amir A Jazaeri
Journal:  Curr Treat Options Oncol       Date:  2017-08-24

Review 6.  T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition.

Authors:  Roch Houot; Liora Michal Schultz; Aurélien Marabelle; Holbrook Kohrt
Journal:  Cancer Immunol Res       Date:  2015-10       Impact factor: 11.151

Review 7.  Effect of Lymphodepletion on Donor T Cells and the Role of Recipient Cells Persisting after Cytotoxic Treatments in Cancer Immunotherapies.

Authors:  Satoshi Watanabe; Masashi Arita; Miho Takahashi; Yu Saida; Toshiyuki Koya; Toshiaki Kikuchi
Journal:  Crit Rev Immunol       Date:  2017       Impact factor: 2.214

8.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 9.  Chimeric Antigen Receptor Therapy.

Authors:  Carl H June; Michel Sadelain
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

10.  Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.

Authors:  I Puzanov; A Diab; K Abdallah; C O Bingham; C Brogdon; R Dadu; L Hamad; S Kim; M E Lacouture; N R LeBoeuf; D Lenihan; C Onofrei; V Shannon; R Sharma; A W Silk; D Skondra; M E Suarez-Almazor; Y Wang; K Wiley; H L Kaufman; M S Ernstoff
Journal:  J Immunother Cancer       Date:  2017-11-21       Impact factor: 13.751
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.